In a study of adults hospitalized between February 2022 and February 2023, when the omicron variant predominated, monovalent mRNA vaccination was 76% effective at preventing COVID-19-associated invasive mechanical ventilation and death up to 6 months after the last dose and 56% effective at least one year after the last dose, the Centers for Disease Control and Prevention reported. 

The Food and Drug Administration this month authorized using a single dose of bivalent mRNA COVID-19 vaccine for primary vaccination as well as for future doses. The Centers for Disease Control and Prevention recommends all adults remain up to date with COVID-19 vaccination, including the updated bivalent vaccine, to prevent critical outcomes of COVID-19. For the latest AHA resources to promote COVID-19 vaccine confidence, visit www.aha.org/vaccineconfidence
 

Related News Articles

#HealthCareInnovation Blog
In the fall of 2021, two years into the COVID-19 pandemic in the U.S., nearly 80% of adults said they had heard “at least one of eight different false…
Headline
The National Institute for Occupational Safety and Health this week revoked eight N95 filtering facepiece respirator approvals and four powered air-…
Headline
The Centers for Medicare and Medicaid Services released a FAQ regarding Consolidated Appropriations Act changes for states redetermining Medicaid enrollee…
Headline
Telehealth Access for America, an AHA-supported campaign to protect patient access to critical telehealth services, urged Congress to make permanent certain…
Headline
The Department of Health and Human Services May 11 amended its Public Readiness and Emergency Preparedness Act declaration for COVID-19 to extend…
Headline
The Department of Health and Human Services yesterday released a fact sheet reviewing how the May 11 end of the COVID-19 public health emergency will…